PATENTS and LICENSES
ITEM 8. NATURE OF ISSUER'S BUSINESS.
NanoViricides, Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a development stage company with several
drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc., to which we have the necessary licenses in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV),
Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. We focus our research and clinical programs on specific anti-viral solutions.
We are seeking to add to our existing portfolio of products through our internal discovery and clinical development programs and through an in-licensing strategy.
The Company owns exclusive worldwide license in perpetuity to technology that enables the creation of “nanoviricides (tm)”. A nanoviricide is a flexible nano-scale material about the size of a few billionths of a meter,that is chemically programmed to specifically target and attack a
particular type of virus, like a guided missile. A nanoviricide also is capable of simultaneously delivering a devastating payload of active ingredients into the virus particle, thereby completely destroying the enemy, like a suicide bomber.
********************
US6,521,736
(Certain specific
amphiphilic polymers).
Issued:
Feb 18, 2003
Feb 18, 2020
N/A TheraCour Pharma and
Univ. of Massachusetts,
Lowell. [Nonexclusive
license from TheraCour
Pharma].
US60/645,491
(Novel theraCour
Materials and their
Uses for Targeted
Drugs).
(Provisional
Application)
Applied:
Jan 18, 2005
Jan 17, 2023
(estimated)
Application to be
filed.
TheraCour Pharma, Inc.
[Exclusive License].
**************************
The significant terms of the license include:
Theracour retains exclusive right to develop and manufacture the drugs against the five types of human viruses. As to any licensed product (i.e. drugs developed pursuant to this agreement), TheraCour agrees that it will manufacture such drug exclusively for the Company, and unless
such license is terminated, will not manufacture such product for its own sake or for others.
Development Fee. Theracour can charge its costs (direct and indirect) plus no more than 30% as a Development Fee.
Royalties. The Company shall pay to Theracour a royalty of 15% on its net sales of Licensed Products.
From:
otcstockinfo.com |
